Navigation Links
Olympus Biotech Names Oliver Burckhardt to President North America
Date:5/23/2011

HOPKINTON, Mass., May 23, 2011 /PRNewswire/ -- Olympus Biotech, an Olympus Corporation company, today announced the appointment of Oliver Burckhardt to the position of president of Olympus Biotech Corporation. In his new role, Mr. Burckhardt will lead the company's North American business and focus on expanding opportunities for the emerging regenerative medicine market. Mr. Burckhardt will also become a member of the Olympus Biotech Board of Directors.

"With nearly 20 years in the medical device industry, Oliver's extensive knowledge of the industry and global leadership experience will prove invaluable as we continue to grow Olympus Biotech," said Hitoshi Mizuno, CEO Olympus Biotech Corporation. "We look forward to benefiting from his immense expertise as we continue to lead the creation of this dynamic new field of medicine."

Before joining Olympus Biotech, Mr. Burckhardt most recently served as the international president and CEO of Scient'x Corp in Paris, France, where his strategic vision redefined the company's direction and resulted in double-digit growth. Mr. Burckhardt also served as president of Orthofix, Inc., where he was responsible for the global spine business unit. Prior to that, Mr. Burckhardt spent nine years with Aesculap, Inc. in various sales and marketing positions, including vice president of sales and marketing for the Aesculap Spine division in the United States.

"The Vision of Olympus Biotech to advance into regenerative medicine is the next logical step in the treatment of many medical pathologies and conditions. I am excited about the overall strategic thinking and the assets that are already in place, within Olympus, which represent a perfect starting point for this future oriented strategy," said Mr. Burckhardt. He added, "I look forward to joining the talented team at Olympus Biotech and leveraging my experience in the industry to generate further growth and success."

About Olympus Biotech Corporation

Olympus Biotech was established in December, 2010 as a wholly owned company of Olympus Corporation. The vision of Olympus Biotech is to improve the patient Quality of Life by developing and distributing Regenerative Medicine that stimulate the intrinsic healing capacity in the living body by the technological development of growth factors and biomaterials.

Media Contact:
Jessica Nelson
Kwittken & Company
(646) 747-7141
jnelson@kwitco.com


'/>"/>
SOURCE Olympus Biotech Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Gumz to Retire as President and CEO of Olympus Corporation of the Americas
2. Stryker Completes Sale of OP-1 for use in Orthopaedic Bone Applications to Olympus
3. Stryker Announces Definitive Agreement to Sell OP-1 for Use in Orthopaedic Bone Applications to Olympus
4. Olympus Launches 2011 National Innovation Awards Program
5. Olympus America Licenses Digital Pathology Patents to BioImagene, Inc.
6. Omnyx Licenses Olympus Digital Pathology Patents
7. Venture-Backed Biotech Generates Quicker Exits but Lower Multiples than Medical Device
8. Generex Biotechnology Corporation CEO Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com
9. Generex Biotechnology Corporation CEO to Present Live, Online at RetailInvestorConferences.com on May 5th
10. Centocor Ortho Biotech Products, L.P. Voluntarily Withdraws NDA for Trabectedin
11. Immune Design Corp. Appoints Pharma and Biotech Executive Carlos V. Paya, MD, PhD as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... ... ... Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and Mental ... exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took place ... BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive an ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
Breaking Medicine News(10 mins):